Sugi Predict

Sugi Predict / Compounds / SCHEMBL1806589

SCHEMBL1806589

SCHEMBL1806589

N#Cc1c(F)cc(I)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TRPV4 Q9HBA0 1/20 0.43
▸ TAS1R3 Q7RTX0 1/20 0.33
▸ TAS1R1 Q7RTX1 1/20 0.33
▸ TAS1R2 Q8TE23 1/20 0.33
▸ KHK P50053 1/20 0.32
▸ EPAS1 Q99814 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ TP53 P04637 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1811343 0.84 ALDH1A1 (0.38) TRPV4MEN1ALDH1A1TP53CYP3A4
SCHEMBL732229 0.84 TRPV4 (0.58) TRPV4
SCHEMBL15129217 0.78 TRPV4 (0.46) TRPV4TAS1R3TAS1R1TAS1R2KHK
SCHEMBL15821506 0.78 TRPV4 (0.46) TRPV4TAS1R3TAS1R1TAS1R2KHK
SCHEMBL16177628 0.75 TRPV4 (0.43) TRPV4TAS1R3TAS1R1TAS1R2CYP3A4
SCHEMBL16545828 0.75 TRPV4 (0.43) TRPV4KHKMEN1MAPTMAPK1
SCHEMBL18305809 0.75 TRPV4 (0.43) TRPV4TAS1R3TAS1R1TAS1R2KHK
SCHEMBL1808542 0.75 TRPV4 (0.43) TRPV4TAS1R3TAS1R1TAS1R2KHK
SCHEMBL31353077 0.73 TRPV4 (0.42) TRPV4TAS1R3TAS1R1TAS1R2KHK
SCHEMBL31372011 0.72 TRPV4 (0.41) TRPV4KHK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025036382-A1 SULFONAMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海复宏汉霖生物医药有限公司 2025-02-20 — — WO disclosed
EP-3885340-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2024-11-27 — — EP disclosed
EP-3885340-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2021-09-29 — — EP disclosed
US-11046713-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2021-06-29 — — US disclosed
EP-3369732-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2021-05-26 — — EP disclosed
US-20200299307-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2020-09-24 — — US disclosed
US-10711013-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2020-07-14 — — US disclosed
US-20190100536-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2019-04-04 — — US disclosed
US-10118933-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2018-11-06 — — US disclosed
EP-3369732-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2018-09-05 — — EP disclosed
US-8921378-B2 Androgen receptor modulating carboxamides ORION CORPORATION (FI) 2014-12-30 — — US disclosed
EP-2493858-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2014-07-02 — — EP disclosed
EP-2699561-A1 ANDROGEN RECEPTOR MODULATING CARBOXAMIDES Orion Corporation (FI) 2014-02-26 — — EP disclosed
CN-103492372-A Androgen receptor modulating carboxamides ORION CORP 2014-01-01 — — CN disclosed
WO-2012143599-A1 ANDROGEN RECEPTOR MODULATING CARBOXAMIDES ORION CORPORATION (FI) 2012-10-26 — — WO disclosed
US-20120225867-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2012-09-06 — — US disclosed
EP-2493858-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS Orion Corporation (FI) 2012-09-05 — — EP disclosed
CN-102596910-A Androgen receptor modulating compounds ORION CORP 2012-07-18 — — CN disclosed
WO-2011051540-A9 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2012-06-21 — — WO disclosed
WO-2011051540-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2011-05-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10118933-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG TRPV4 1537/4885TAS1R3 2272/4885TAS1R1 2180/4885
US-10711013-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG TRPV4 1537/4885TAS1R3 2272/4885TAS1R1 2180/4885
US-20200299307-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG TRPV4 1537/4885TAS1R3 2272/4885TAS1R1 2180/4885
US-20190100536-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG TRPV4 1537/4885TAS1R3 2272/4885TAS1R1 2180/4885
US-11046713-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG TRPV4 1537/4885TAS1R3 2272/4885TAS1R1 2180/4885
US-20120225867-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG TRPV4 1537/4885TAS1R3 2272/4885TAS1R1 2180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.